Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
Clinical trial NCT00098332 · COMPLETED
Trial details
- NCT number
- NCT00098332
- Sponsor
- BioCryst Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2004-11-01
- Primary completion
- 2010-12-01
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.